While phase II metabolism generally aims to detoxify compounds, in some cases, it can lead to the formation of toxic metabolites. For example, the acetylation of certain arylamines can produce carcinogenic N-acetoxy derivatives. Understanding these exceptions is crucial for risk assessment and the development of safer pharmaceuticals.
